Allogene Therapeutics, Inc. (ALLO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Arie S. Belldegrun F.A.C.S., M.D. | Co-Founder & Executive Chairman | 685.29k | -- | 1949 |
| Dr. David D. Chang M.D., Ph.D. | Co-Founder, President, CEO & Director | 1.06M | -- | 1960 |
| Mr. Joshua A. Kazam | Co-Founder & Director | 54k | -- | 1977 |
| Dr. Zachary J. Roberts M.D., Ph.D. | Executive VP of Research & Development and Chief Medical Officer | 714.75k | -- | 1978 |
| Mr. Geoffrey M. Parker | Executive VP & CFO | -- | -- | 1965 |
| Mr. Benjamin M. Beneski | Senior VP & Chief Technical Officer | -- | -- | 1977 |
| Mr. Earl M. Douglas Esq. | Senior VP, General Counsel, Compliance Officer & Corporate Secretary | -- | -- | 1963 |
| Ms. Susan R. Lundeen | Chief People Officer | -- | -- | 1966 |
| Ms. Christine Cassiano | Executive VP, Chief Corporate Affairs & Brand Strategy Officer | -- | -- | -- |
| Ms. Annie Yoshiyama | SVP & Corporate Controller | -- | -- | 1984 |
Allogene Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 226
Description
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Corporate Governance
Upcoming Events
August 6, 2025 at 8:00 PM UTC
Allogene Therapeutics, Inc. Earnings Date